NO20072444L - Carbamate compounds for use in the treatment of neurodegenerative disorders - Google Patents
Carbamate compounds for use in the treatment of neurodegenerative disordersInfo
- Publication number
- NO20072444L NO20072444L NO20072444A NO20072444A NO20072444L NO 20072444 L NO20072444 L NO 20072444L NO 20072444 A NO20072444 A NO 20072444A NO 20072444 A NO20072444 A NO 20072444A NO 20072444 L NO20072444 L NO 20072444L
- Authority
- NO
- Norway
- Prior art keywords
- formula
- group
- alkyl
- phenyl
- treatment
- Prior art date
Links
- 150000004657 carbamic acid derivatives Chemical class 0.000 title 1
- 208000015122 neurodegenerative disease Diseases 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 abstract 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 abstract 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 abstract 1
- 229910052794 bromium Inorganic materials 0.000 abstract 1
- 229910052801 chlorine Inorganic materials 0.000 abstract 1
- 239000000460 chlorine Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 239000011737 fluorine Substances 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 229910052740 iodine Inorganic materials 0.000 abstract 1
- 239000011630 iodine Substances 0.000 abstract 1
- 230000004112 neuroprotection Effects 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
Abstract
Oppfinnelsen angår fremgangsmåter for å tilveiebringe neuroproteksjon og omfatter administrering til et individ som trenger det, av en terapeutisk effektiv mengde av en forbindelse valgt fra gruppen bestående av Formel (I) og Formel II), eller et farmasøytisk akseptabelt salt eller en ester derav: I Formel (I) og Formel (II) er fenyl substituert ved X med 1-4 halogenatomer valgt fra gruppen bestående av fluor, klor, brom og jod; og R1, R2, R3, R4, R5 og R6 uavhengig er valgt fra gruppen bestående av hydrogen og C1-4-alkyl, der C1-4-alkyl eventuelt er substituert med fenyl (der fenyl eventuelt er substituert med substituenter uavhengig valgt fra gruppen bestående av halogen, C1-4-alkyl, C1-4-alkoksy, amino, nitro og cyano).The invention relates to methods for providing neuroprotection and comprises administering to a subject in need thereof a therapeutically effective amount of a compound selected from the group consisting of Formula (I) and Formula II), or a pharmaceutically acceptable salt or ester thereof: Formula (I) and Formula (II) are phenyl substituted by X having 1-4 halogen atoms selected from the group consisting of fluorine, chlorine, bromine and iodine; and R 1, R 2, R 3, R 4, R 5 and R 6 are independently selected from the group consisting of hydrogen and C 1-4 alkyl, wherein C 1-4 alkyl is optionally substituted with phenyl (wherein phenyl is optionally substituted with substituents independently selected from the group consisting of halogen, C 1-4 alkyl, C 1-4 alkoxy, amino, nitro and cyano).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61940204P | 2004-10-15 | 2004-10-15 | |
| US69840305P | 2005-07-12 | 2005-07-12 | |
| PCT/US2005/036695 WO2006044472A1 (en) | 2004-10-15 | 2005-10-14 | Carbamate compounds for use in treating neurodegenerative disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20072444L true NO20072444L (en) | 2007-06-14 |
Family
ID=35840528
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20072444A NO20072444L (en) | 2004-10-15 | 2007-05-11 | Carbamate compounds for use in the treatment of neurodegenerative disorders |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP1802294A1 (en) |
| JP (1) | JP2008516961A (en) |
| KR (3) | KR20070085309A (en) |
| AU (1) | AU2005295787A1 (en) |
| BR (1) | BRPI0516112A (en) |
| CA (1) | CA2584854A1 (en) |
| EA (1) | EA200700871A1 (en) |
| EC (1) | ECSP077395A (en) |
| IL (1) | IL182432A0 (en) |
| MX (1) | MX2007004491A (en) |
| NI (1) | NI200700094A (en) |
| NO (1) | NO20072444L (en) |
| SG (1) | SG142306A1 (en) |
| WO (1) | WO2006044472A1 (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2509596B1 (en) | 2009-12-08 | 2019-08-28 | Case Western Reserve University | Gamma aminoacids for treating ocular disorders |
| US8609849B1 (en) | 2010-11-30 | 2013-12-17 | Fox Chase Chemical Diversity Center, Inc. | Hydroxylated sulfamides exhibiting neuroprotective action and their method of use |
| US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
| US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
| KR20190081385A (en) | 2017-12-29 | 2019-07-09 | 강원대학교산학협력단 | Composition for preventing the ischemia stroke disease containing oxcarbazepine |
| FR3110393B1 (en) * | 2020-05-20 | 2022-05-06 | Grn Consulting | COMPOUND AND COMPOSITION FOR INDUCING NEUROPROTECTION |
| KR20230044274A (en) * | 2020-08-31 | 2023-04-03 | (주)바이오팜솔루션즈 | Phenyl alkyl carbamate compounds for preventing or treating neurodegenerative diseases |
| KR20230051206A (en) | 2020-09-10 | 2023-04-17 | (주)바이오팜솔루션즈 | Sulfamate derivative compounds for the treatment or alleviation of mental disorders |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5698588A (en) * | 1996-01-16 | 1997-12-16 | Yukong Limited | Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol |
| US20010034365A1 (en) * | 1996-01-16 | 2001-10-25 | Choi Yong Moon | Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol |
| HUP0203198A3 (en) * | 1999-08-20 | 2005-07-28 | Ortho Mcneil Pharm Inc | Pharmaceutical composition comprising a tramadol material and an anticonvulsant drug, process for its preparation and its use |
| EP1383489B1 (en) * | 2001-02-27 | 2007-05-09 | Ortho-Mcneil Pharmaceutical, Inc. | Carbamate compounds for use in preventing or treating neurodegenerative disorders |
| DK1809273T3 (en) * | 2004-09-16 | 2010-08-02 | Janssen Pharmaceutica Nv | Use of 2-phenyl-1,2-ethanediol (di) carbamates for the treatment of epileptogenesis |
-
2005
- 2005-10-14 BR BRPI0516112-6A patent/BRPI0516112A/en not_active IP Right Cessation
- 2005-10-14 MX MX2007004491A patent/MX2007004491A/en unknown
- 2005-10-14 EP EP05810159A patent/EP1802294A1/en not_active Withdrawn
- 2005-10-14 NI NI200700094A patent/NI200700094A/en unknown
- 2005-10-14 SG SG200802877-1A patent/SG142306A1/en unknown
- 2005-10-14 KR KR1020077010744A patent/KR20070085309A/en not_active Ceased
- 2005-10-14 WO PCT/US2005/036695 patent/WO2006044472A1/en not_active Ceased
- 2005-10-14 CA CA002584854A patent/CA2584854A1/en not_active Abandoned
- 2005-10-14 KR KR1020117007395A patent/KR20110049901A/en not_active Ceased
- 2005-10-14 AU AU2005295787A patent/AU2005295787A1/en not_active Abandoned
- 2005-10-14 JP JP2007536843A patent/JP2008516961A/en active Pending
- 2005-10-14 EA EA200700871A patent/EA200700871A1/en unknown
- 2005-10-14 KR KR1020097019737A patent/KR20090130175A/en not_active Ceased
-
2007
- 2007-04-10 IL IL182432A patent/IL182432A0/en unknown
- 2007-04-13 EC EC2007007395A patent/ECSP077395A/en unknown
- 2007-05-11 NO NO20072444A patent/NO20072444L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| KR20090130175A (en) | 2009-12-18 |
| IL182432A0 (en) | 2007-09-20 |
| KR20070085309A (en) | 2007-08-27 |
| WO2006044472A1 (en) | 2006-04-27 |
| MX2007004491A (en) | 2007-08-08 |
| AU2005295787A1 (en) | 2006-04-27 |
| BRPI0516112A (en) | 2008-08-26 |
| KR20110049901A (en) | 2011-05-12 |
| CA2584854A1 (en) | 2006-04-27 |
| SG142306A1 (en) | 2008-05-28 |
| ECSP077395A (en) | 2007-05-30 |
| EA200700871A1 (en) | 2007-10-26 |
| JP2008516961A (en) | 2008-05-22 |
| EP1802294A1 (en) | 2007-07-04 |
| NI200700094A (en) | 2008-02-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20080739L (en) | Methods for Treating Epileptogenesis | |
| NO20072444L (en) | Carbamate compounds for use in the treatment of neurodegenerative disorders | |
| NO20080738L (en) | Methods of neuroprotection | |
| NO20071921L (en) | Methods for treating epileptogenesis and epilepsy | |
| YU67703A (en) | Carbamate compounds for use in preventing or treating movement disorders | |
| MY138156A (en) | Carbamate compounds for use in preventing or treating neurodegenerative disorders | |
| MY133370A (en) | Carbamate compounds for use in preventing or treating bipolar disorders | |
| IL157590A0 (en) | Carbamate compounds for use in preventing or treating bipolar disorder | |
| EA200701536A1 (en) | WAYS OF QT INTERVAL CONTROL | |
| IL157594A0 (en) | Carbamate compounds for use in preventing or treating anxiety disorders | |
| BG106806A (en) | NEW COMPOUNDS | |
| NO20033801L (en) | Carbamate compounds for use in the prevention or treatment of psychotic disorders | |
| NO20091658L (en) | Procedure for the treatment of colitis and vestibular disorders | |
| EA200800422A1 (en) | METHODS OF TREATMENT OF DISEASES DETERMINED BY CHEMICALS | |
| EA200700322A1 (en) | OXAZOLIDINONS CONTAINING OXINDOLS AS ANTIBACTERIAL AGENTS | |
| NO20040176L (en) | Carbamate compounds for use in the prevention or therapy of neuropathic pain and cluster and migraine headache-associated pain | |
| MY136733A (en) | Carbamate compounds for use in preventing or treating psychotic disorders | |
| TW200701978A (en) | Methods of treating epileptogenesis and epilepsy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |